VJHemOnc is committed to improving our service to you

SOHO 2020 | Updates from AMG 330 in AML

VJHemOnc is committed to improving our service to you

Marion Subklewe

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, updates us on the use of AMG 330, a novel bispecific T-cell engager antibody construct in relapsed/refractory acute myeloid leukemia (AML), as well as efforts being made to mitigate the incidence of cytokine release syndrome. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter